HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okada, S. Articles by Kita, H. Search for Related Content PubMed PubMed Citation Articles by Okada, S. Articles by Kita, H.

Lidocaine and its Analogues Inhibit IL-5-Mediated Survival and Activation of Human Eosinophils¹

Departments of Immunology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905

Eosinophils and cytokines active on eosinophils, especially IL-5, are believed to be critically involved in chronic allergic diseases. IL-5 activates eosinophils and enhances their survival in vitro by delaying apoptosis. In this study, we found that lidocaine and six analogues blunt responses of eosinophils to IL-5. Lidocaine and its derivatives inhibit IL-5-mediated eosinophil survival in a concentration-dependent manner (IC₅₀ = 110 µM for 30 pg/ml IL-5). At suboptimal lidocaine concentrations, the eosinophil survival response to IL-5 shifts and more IL-5 is required to maintain survival. The inhibitory effect requires at least 24-h exposure of eosinophils to lidocaine, and the protein kinase C activator, PMA, completely reverses the inhibition. A multiparameter flow-cytometric analysis shows that lidocaine hastens the apoptosis of eosinophils normally delayed by IL-5. Lidocaine does not affect IL-5R expression or IL-5-induced protein tyrosine phosphorylation. Lidocaine also inhibits eosinophil survival mediated by IL-3 or granulocyte-macrophage CSF, although less potently than that mediated by IL-5. Furthermore, lidocaine inhibits eosinophil superoxide production stimulated by IL-5, granulocyte-macrophage CSF, or IL-3, but not that stimulated by platelet-activating factor, immobilized IgG, or PMA. Lidocaine and its derivatives show novel immunomodulatory properties and are able to blunt eosinophil responses to cytokines in addition to their local anesthetic or antiarrhythmic properties. Thus, lidocaine and its derivatives may represent a new class of therapeutic agents to treat patients with allergic diseases.

This article has been cited by other articles:

				M. Duong, A. M. Wilson, L. Jayaram, M. Dolovich, and F. Hargreave The effect of inhaled lidocaine-hydrofluoroalkane 134a in prednisone-dependent eosinophilic bronchitis Eur. Respir. J., October 1, 2008; 32(4): 1119 - 1122. [Full Text] [PDF]

				N. Farahi, A. S. Cowburn, P. D. Upton, J. Deighton, A. Sobolewski, E. Gherardi, N. W. Morrell, and E. R. Chilvers Eotaxin-1/CC Chemokine Ligand 11: A Novel Eosinophil Survival Factor Secreted by Human Pulmonary Artery Endothelial Cells J. Immunol., July 15, 2007; 179(2): 1264 - 1273. [Abstract] [Full Text] [PDF]

				M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]

				J.-T. Kim, A. W. Schimming, and H. Kita Ligation of Fc{gamma}RII (CD32) Pivotally Regulates Survival of Human Eosinophils J. Immunol., April 1, 1999; 162(7): 4253 - 4259. [Abstract] [Full Text] [PDF]

				J. L. Bankers-Fulbright, G. M. Kephart, D. A. Loegering, A. L. Bradford, S. Okada, H. Kita, and G. J. Gleich Sulfonylureas Inhibit Cytokine-Induced Eosinophil Survival and Activation J. Immunol., June 1, 1998; 160(11): 5546 - 5553. [Abstract] [Full Text] [PDF]